Primary cutaneous marginal zone lymphoma: Difference between revisions
No edit summary |
CSV import |
||
| Line 1: | Line 1: | ||
{{ | {{Short description|A type of skin lymphoma}} | ||
| | |||
'''Primary cutaneous marginal zone lymphoma''' (PCMZL) is a type of [[extranodal marginal zone B-cell lymphoma]] that primarily affects the skin. It is classified as a low-grade [[B-cell lymphoma]] and is part of the group of [[mucosa-associated lymphoid tissue (MALT) lymphomas]]. PCMZL is characterized by the proliferation of small B-cells, including marginal zone cells, monocytoid cells, and small lymphocytes, often with reactive germinal centers. | |||
== | ==Clinical Presentation== | ||
PCMZL typically presents as solitary or multiple skin lesions, which may appear as red or violaceous papules, nodules, or plaques. These lesions are most commonly found on the arms, trunk, or back, but can occur anywhere on the body. The condition is generally indolent, meaning it progresses slowly and is often asymptomatic. | |||
== | ==Pathophysiology== | ||
The exact cause of PCMZL is not well understood, but it is thought to be associated with chronic antigenic stimulation. This can be due to infections, such as [[Borrelia burgdorferi]] (the bacterium responsible for [[Lyme disease]]), or autoimmune conditions. The lymphoma cells in PCMZL are typically CD20 positive and may express other B-cell markers such as CD79a and Bcl-2, but they are usually negative for CD5, CD10, and cyclin D1. | |||
[[ | ==Diagnosis== | ||
[[ | Diagnosis of PCMZL is based on clinical examination, histopathological analysis, and immunohistochemical staining of a skin biopsy. The biopsy typically shows a dense infiltrate of small B-cells in the dermis, often with reactive germinal centers. Molecular studies may reveal clonal immunoglobulin gene rearrangements, supporting the diagnosis of a B-cell lymphoma. | ||
==Treatment== | |||
Treatment options for PCMZL depend on the extent and location of the disease. Localized lesions may be treated with surgical excision or [[radiation therapy]]. In cases with multiple lesions or more extensive disease, systemic therapies such as [[rituximab]] (an anti-CD20 monoclonal antibody) or low-dose [[chemotherapy]] may be considered. The prognosis for PCMZL is generally favorable, with a high rate of long-term survival. | |||
==Prognosis== | |||
PCMZL is considered an indolent lymphoma with an excellent prognosis. Most patients experience long-term survival, and the disease rarely progresses to a more aggressive form. However, recurrences are common, and ongoing monitoring is recommended. | |||
==Related Pages== | |||
* [[Lymphoma]] | |||
* [[B-cell lymphoma]] | |||
* [[Mucosa-associated lymphoid tissue lymphoma]] | |||
* [[Cutaneous lymphoma]] | |||
* [[Borrelia burgdorferi]] | |||
[[Category:Lymphoma]] | |||
[[Category:Dermatology]] | |||
[[Category:Hematology]] | |||
Revision as of 19:18, 22 March 2025
A type of skin lymphoma
Primary cutaneous marginal zone lymphoma (PCMZL) is a type of extranodal marginal zone B-cell lymphoma that primarily affects the skin. It is classified as a low-grade B-cell lymphoma and is part of the group of mucosa-associated lymphoid tissue (MALT) lymphomas. PCMZL is characterized by the proliferation of small B-cells, including marginal zone cells, monocytoid cells, and small lymphocytes, often with reactive germinal centers.
Clinical Presentation
PCMZL typically presents as solitary or multiple skin lesions, which may appear as red or violaceous papules, nodules, or plaques. These lesions are most commonly found on the arms, trunk, or back, but can occur anywhere on the body. The condition is generally indolent, meaning it progresses slowly and is often asymptomatic.
Pathophysiology
The exact cause of PCMZL is not well understood, but it is thought to be associated with chronic antigenic stimulation. This can be due to infections, such as Borrelia burgdorferi (the bacterium responsible for Lyme disease), or autoimmune conditions. The lymphoma cells in PCMZL are typically CD20 positive and may express other B-cell markers such as CD79a and Bcl-2, but they are usually negative for CD5, CD10, and cyclin D1.
Diagnosis
Diagnosis of PCMZL is based on clinical examination, histopathological analysis, and immunohistochemical staining of a skin biopsy. The biopsy typically shows a dense infiltrate of small B-cells in the dermis, often with reactive germinal centers. Molecular studies may reveal clonal immunoglobulin gene rearrangements, supporting the diagnosis of a B-cell lymphoma.
Treatment
Treatment options for PCMZL depend on the extent and location of the disease. Localized lesions may be treated with surgical excision or radiation therapy. In cases with multiple lesions or more extensive disease, systemic therapies such as rituximab (an anti-CD20 monoclonal antibody) or low-dose chemotherapy may be considered. The prognosis for PCMZL is generally favorable, with a high rate of long-term survival.
Prognosis
PCMZL is considered an indolent lymphoma with an excellent prognosis. Most patients experience long-term survival, and the disease rarely progresses to a more aggressive form. However, recurrences are common, and ongoing monitoring is recommended.
